Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 43, Issue 2, 2014, Pages 85-90

  Neregard P ^a   Krishnamurthy, A ^a   Revu, S ^a   Engstrom M ^a   Af Klint, E ^a   Catrina, A I ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTHROSCOPY; ARTICLE; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; JOINT BIOPSY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROSCOPY; BIOPSY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; SYNOVIAL MEMBRANE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84895727203     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2013.834964     Document Type: Article

References (18)

1. Feldmann M, Brennan FM, Foxwell BM, Maini RN. The role of TNF alpha and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 2001;3:188-99
2. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008;117:244-79
3. Makrygiannakis D, Catrina AI. Apoptosis as a mechanism of action of tumor necrosis factor antagonists in rheumatoid arthritis. J Rheumatol 2012;39:679-85
4. Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P. True infliximab resistance in rheumatoid arthritis: A role for lymphotoxin alphä Ann Rheum Dis 2004;63:1344-6
5. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Emery P, et al. Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept. Arthritis Care Res 2007;57:448-53
6. Bingham CO 3rd, Ince A, Haraoui B, Keystone EC, Chon Y, Baumgartner S. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. Curr Med Res Opin 2009;25:1131-42
7. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
8. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
9. van GestelAM, Prevoo ML, van 't Hof MA, van RijswijkMH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39: 34-40
10. af Klint E, Catrina AI, Matt P, Neregrad P, Lampa J, Ulfgren AK, et al. Evaluation of arthroscopy and macroscopic scoring. Arthritis Res Ther 2009;11:R81
11. Calmon-Hamaty F, Combe B, Hahne M, Morel J. Lymphotoxin α revisited: General features and implications in rheumatoid arthritis. Arthritis Res Ther 2011;13:232
12. Ulfgren AK, Grondal L, Lindblad S, Khademi M, Johnell O, Klareskog L, et al. Interindividual and intra-Articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: Potential implications for treatment. Ann Rheum Dis 2000;59:439-47
13. Smeets TJ, Kraan MC, van Loon ME, Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62
14. Catrina AI, Trollmo C, af Klint E, Engstrom M, Lampa J, Hermansson Y, et al. Evidence that anti-Tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report. Arthritis Rheum 2005;52:61-72
15. Suzuki Y, Inoue K, Chiba J, Inoue Y, Kanbe K. Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis. Int J Rheum Dis 2009;12:7-13
16. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann Rheum Dis 2008;67:1139-44
17. Ulfgren AK, Andersson U, Engstrom M, Klareskog L, Maini RN, Taylor PC. Systemic anti-Tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum 2000;43:2391-6
18. Buch MH, Reece RJ, Quinn MA, English A, Cunnane G, Henshaw K, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 2008;47:1469-75